Century Therapeutics IPSC Stock
Century Therapeutics Price Chart
Century Therapeutics IPSC Financial and Trading Overview
| Century Therapeutics stock price | 2.41 USD |
| Previous Close | 2.29 USD |
| Open | 2.29 USD |
| Bid | 1.73 USD x 200 |
| Ask | 2.95 USD x 200 |
| Day's Range | 2.27 - 2.41 USD |
| 52 Week Range | 0.44 - 3.04 USD |
| Volume | 904.75K USD |
| Avg. Volume | 987.33K USD |
| Market Cap | 414.82M USD |
| Beta (5Y Monthly) | 1.566 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 USD |
IPSC Valuation Measures
| Enterprise Value | 328.04M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.0273223 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | |
| Price/Book (mrq) | 1.5646257 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.229 |
Trading Information
Century Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.566 |
| 52-Week Change | 286.55% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 3.04 USD |
| 52 Week Low | 0.44 USD |
| 50-Day Moving Average | 2.28 USD |
| 200-Day Moving Average | 1.52 USD |
IPSC Share Statistics
| Avg. Volume (3 month) | 987.33K USD |
| Avg. Daily Volume (10-Days) | 790.55K USD |
| Shares Outstanding | 180.35M |
| Float | 97.86M |
| Short Ratio | 16.45 |
| % Held by Insiders | 12.05% |
| % Held by Institutions | 78.46% |
| Shares Short | 12.47M |
| Short % of Float | 6.95% |
| Short % of Shares Outstanding | 6.90% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.28% |
| Return on Equity (ttm) | -42.67% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -86192000 USD |
| EBITDA | -101596000 USD |
| Net Income Avi to Common (ttm) | -107785000 USD |
| Diluted EPS (ttm) | -1.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 134.8M USD |
| Total Cash Per Share (mrq) | 0.75 USD |
| Total Debt (mrq) | 48.03M USD |
| Total Debt/Equity (mrq) | 18.14 USD |
| Current Ratio (mrq) | 10.249 |
| Book Value Per Share (mrq) | 1.47 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -94515000 USD |
| Levered Free Cash Flow (ttm) | -53628000 USD |
Profile of Century Therapeutics
| Country | United States |
| State | PA |
| City | Philadelphia |
| Address | 25 North 38th Street |
| ZIP | 19104 |
| Phone | 267 817 5790 |
| Website | https://www.centurytx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 78 |
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Century Therapeutics Stock
What is a current IPSC stock price?
Century Therapeutics IPSC stock price today per share is 2.41 USD.
How to purchase Century Therapeutics stock?
You can buy IPSC shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Century Therapeutics?
The stock symbol or ticker of Century Therapeutics is IPSC.
Which industry does the Century Therapeutics company belong to?
The Century Therapeutics industry is Biotechnology.
How many shares does Century Therapeutics have in circulation?
The max supply of Century Therapeutics shares is 180.35M.
What is Century Therapeutics Price to Earnings Ratio (PE Ratio)?
Century Therapeutics PE Ratio is now.
What was Century Therapeutics earnings per share over the trailing 12 months (TTM)?
Century Therapeutics EPS is -1.14 USD over the trailing 12 months.
Which sector does the Century Therapeutics company belong to?
The Century Therapeutics sector is Healthcare.
Century Therapeutics IPSC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
NYSE Composite Index
NYA
US
|
23463.63 USD — |
-0.56
|
— — | — — | — — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}